Breast Cancer
Breast Cancer Surgery in a Pandemic: What's the Best Approach?
April 08, 2021
Article
A breast surgeon discusses the best practices for breast cancer surgery during the COVID-19 pandemic.
FDA Approves Sacituzumab Govitecan for Pretreated, Metastatic TNBC
April 07, 2021
Article
The FDA granted a regular approval to sacituzumab govitecan (Trodelvy) for previously treated patients with unresectable locally advanced or metastatic triple-negative breast cancer.
T-DM1 Toxicity Management in Breast Cancer
April 05, 2021
Article
Data from the pivotal phase 3 KATHERINE has led to the addition of ado-trastuzumab emtansine to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it.
BLA Submitted for F-627 to Treat Chemo-Induced Neutropenia in Breast Cancer
April 01, 2021
Article
A biologics license application has been submitted to the FDA for the approval of F-627 as a treatment option for patients with breast cancer who have chemotherapy-induced neutropenia.
FDA Defers Decision on Pembrolizumab for TNBC: Here's Why
March 30, 2021
Article
Ahead of the Prescription Drug User Fee Act action date for the application, the regulatory agency’s Oncologic Drugs Advisory Committee voted 10 to 0 that a decision be deferred until further findings from KEYNOTE-522 trial become available.
Palbociclib/Letrozole Improves Survival in HR+ Metastatic Breast Cancer
March 26, 2021
Article
Palbociclib in combination with endocrine therapy resulted in improved survival outcomes in a real-world population of patients with hormone receptor–positive, HER2-negative, metastatic breast cancer vs letrozole alone in the first-line setting.
Preventing Paclitaxel-Related Infusion Reactions
March 24, 2021
Article
Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel.
Immunotherapy and ADCs Make Headway in Metastatic TNBC
March 22, 2021
Article
Anthracyclines and taxanes remain a backbone in the early-stage setting of triple-negative breast cancer as further evaluations of immunotherapy in the neoadjuvant and adjuvant settings needs to be conducted—efforts that will continue to shape the treatment paradigm.
Study Explores Actionable Pathologic Variants in Caribbean Women With Breast or Ovarian Cancer
March 11, 2021
Article
One in 7 Caribbean-born individuals with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, which provides the opportunity for the utilization of targeted therapeutics and precise prevention strategies.
Improve Breast Cancer Survivorship With Cardio-Oncology Strategies
March 09, 2021
Article
Treatment strategies for patients with breast cancer, especially the combination of anthracyclines and HER2-targeted therapies, come with an increased risk of heart failure and cardiac toxicity.